 |
Vol.62 No.1 contents | Japanese/English |
 | Full Text of PDF (1454K) Article in Japanese |
- Case Report -
Osimertinib for Brain Metastasis of Epidermal Growth Factor Receptor-mutated Squamous Cell Lung Cancer
Suguru Fujita1, Kosuke Hamai1, Shinpei Tada1, Mirai Matsumura1, Sayaka Ueno1, Takuya Tanimoto1, Nobuhisa Ishikawa11Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan
Background. Epidermal growth factor receptor (EGFR) mutation-positive squamous cell lung cancer is rare, and the effect of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) on these lesions is inferior to that for lung adenocarcinoma. Osimertinib is more effective against central nervous system metastases than gefitinib and afatinib and is expected to be effective against brain metastases of EGFR mutation-positive squamous cell lung cancer. However, no studies have investigated the efficacy of osimertinib against brain metastases of EGFR mutation-positive squamous cell lung cancer. Case. A 72-year-old woman was diagnosed with squamous cell lung cancer (T1bN2M0, stage IIIA) harboring an EGFR mutation (exon19 deletion). Two years after receiving chemoradiotherapy, she visited a nearby medical neurosurgery clinic because of a difficulty speaking. Head contrast-enhanced magnetic resonance imaging (MRI) revealed a mass lesion in the left frontal lobe. She underwent craniotomy at the same hospital and was diagnosed with brain metastasis from squamous cell lung cancer; therefore, she was referred to our hospital. Head MRI on admission showed the recurrence of brain metastasis near the excision cavity, and she was administered osimertinib. After the initiation of osimertinib treatment, the brain metastasis markedly shrank, and she continued to receive osimertinib for 20 months. Conclusion. For EGFR mutation-positive lung cancer with brain metastases, osimertinib may be useful, even in cases of squamous cell carcinoma.
key words: EGFR mutation, Squamous cell lung cancer, Brain metastasis, Osimertinib
Received: March 10, 2021
Accepted: September 7, 2021
JJLC 62 (1): 33-37, 2022
